Grifols SA (GRFS)
6.27
-0.12
(-1.88%)
USD |
NASDAQ |
Apr 25, 16:00
6.27
0.00 (0.00%)
After-Hours: 16:42
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.258B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -14.80% |
| Valuation | |
| PE Ratio | 20.15 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.5903 |
| Price to Book Value | 0.6610 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.546 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.82% |
Profile
| As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
| URL | https://www.grifols.com |
| Investor Relations URL | https://www.grifols.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Jul. 26, 2024 (est.) |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 03, 2021 |
Ratings
Profile
| As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
| URL | https://www.grifols.com |
| Investor Relations URL | https://www.grifols.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Jul. 26, 2024 (est.) |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 03, 2021 |